| Autor: |
Gramont, Aimery, Chibaudel, Benoist, Perez-Staub, Nathalie, Dumont, Sarah, Larsen, Annette, André, Thierry |
| Zdroj: |
Current Colorectal Cancer Reports; Sep2014, Vol. 10 Issue 3, p329-338, 10p |
| Abstrakt: |
Adjuvant colon cancer trials compare survival of patients receiving either a standard, approved regimen or a new investigational treatment after curative surgical resection of tumor. The target accrual of trials is on the basis of the statistical power required to reveal survival benefit, and depends on predefined hypotheses regarding the expected results for the control group and the differences in treatment effects between the control and the investigational group. In this review we assess the validity of predefined hypotheses in phase III adjuvant trials of colon cancer treatment published between 1988 and 2012. Correlation between expected and observed results was weak for both the control and the investigational groups in the colon cancer trials. Three-year disease-free survival (DFS) was found to be the most reliable endpoint for assessing different fluoropyrimidine-based and oxaliplatin-based regimens, despite a Will Rogers effect associated with the latter. In recent colon cancer adjuvant trials, correlation between DFS and overall survival was weaker than in previous trials performed when only fluoropyrimidines were available for treatment, both in the adjuvant and metastatic setting. This finding is mainly the result of increased survival obtained with new therapy for patients who relapse after adjuvant therapy. Our observations further support the use of three-year DFS as the primary endpoint of adjuvant chemotherapy trials enrolling patients with stage III colon cancer. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink